USFDA Flags Compliance Issues at Novo Nordisk's New Jersey Facility Written By sheeba farhat12 March 2026 10:30 AM ISTCopenhagen: Novo Nordisk said on Tuesday it had received a warning letter from the U.S. Food and Drug Administration regarding an inspection at the...
Pfizer's GLP-1 Drug Xianweiying Wins China Approval for Long-Term Weight Management Written By sheeba farhat8 March 2026 11:30 AM ISTShanghai: China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, the US drugmaker said...
India's Semaglutide Market Set for Generic Boom as Patents Expire, Over 50 Brands Lined Up for Launch, See Full List Written By Farhat Nasim4 March 2026 10:15 PM ISTNew Delhi: The expiry of semaglutide's key patent in India in March 2026 is ushering in a tsunami of generic versions of the blockbuster diabetes and...
Novo Nordisk to Invest USD 506 Million to Expand Oral GLP-1 Drug Manufacturing in Ireland Written By sheeba farhat3 March 2026 8:46 PM ISTNew Delhi: Novo Nordisk said on Monday it will invest 432 million euros (USD 506.43 million) to expand its manufacturing facility in Athlone,...
CagriSema Fails to Demonstrate Noninferiority to Tirzepatide for Weight Loss: Phase 3 REDEFINE Trial Written By Dr. Kamal Kant Kohli24 Feb 2026 9:15 AM ISTTopline results from a phase 3 clinical trial compared CagriSema with tirzepatide in patients with obesity. CagriSema is a fixed-dose combination of...
USFDA Flags Novo Nordisk's Wegovy Advertisement as False, Seeks Immediate Action Written By sheeba farhat11 Feb 2026 8:19 PM ISTUSFDA said the television spot misleadingly suggests that Wegovy in its pill form offers an advancement or improvement over other weight-loss drugs...
Novo Nordisk Loses USD 50 Billion as Obesity Drug Price War Triggers Profit, Sales Warning Written By sheeba farhat6 Feb 2026 11:15 AM ISTNew Delhi: Novo Nordisk's shares tumbled on Wednesday, knocking nearly USD 50 billion in value from the Danish obesity drug giant, as it warned that...
Emcure Beats 9 Rivals to Secure Second Semaglutide Brand from Novo Nordisk for India Written By Parthika Patel5 Feb 2026 10:31 PM ISTNew Delhi: Emcure Pharmaceuticals has secured exclusive rights to market a second brand of semaglutide in India through a partnership with Novo...
Roche's Experimental Obesity Drug Delivers Up to 22.5% Weight Loss in Phase-II Trial Written By sheeba farhat28 Jan 2026 4:46 PM ISTRoche's experimental obesity drug CT-388 reduces appetite and is in the same class as Lilly's market-leading Zepbound, also known as tirzepatide and...
US Wholesaler Files Class Action Against Novo Nordisk Over Diabetes Drug Victoza Monopoly Claims Written By sheeba farhat27 Jan 2026 2:47 PM ISTSmith Drug asked the court for an unspecified amount of monetary damages on behalf of a proposed class of Victoza purchasers.
Novo Nordisk's Wegovy Gets UK Nod for Higher 7.2 mg Weekly Dose in Obesity Treatment Written By sheeba farhat17 Jan 2026 4:06 PM ISTThe authorisation for the drug, chemically known as semaglutide, covers only patients with a body mass index of 30 or higher using the drug for weight...
No Link to Suicidal Thoughts: USFDA Seeks Label Change for Popular Weight-Loss Drugs Wegovy, Zepbound Written By sheeba farhat14 Jan 2026 6:57 PM ISTThe warnings, part of their original approval, were based on reports of such events observed with a variety of older medicines used or studied for...
